{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:13:24Z","timestamp":1790230404513,"version":"4.1.0"},"reference-count":85,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1001\/jamainternmed.2018.4710","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T17:43:58Z","timestamp":1538588638000},"page":"1586","source":"Crossref","is-referenced-by-count":136,"title":["Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology"],"prefix":"10.1001","volume":"178","author":[{"given":"Bruno","family":"Kovic","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Alberta PROMs & EQ-5D Research & Support Unit, School of Public Health, University of Alberta, Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean Alexander","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Hylands","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Universit\u00e9 de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Pedziwiatr","sequence":"additional","affiliation":[{"name":"2nd Department of General Surgery, Jagiellonian University Medical College, Krakow, Poland"},{"name":"Centre for Research, Training and Innovation in Surgery (CERTAIN Surgery), Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Kurashiki Central Hospital, Miwa Kurashiki Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Gomaa","sequence":"additional","affiliation":[{"name":"High Institute of Public Health, Alexandria University, Al Ibrahimeyah Qebli WA Al Hadrah Bahri Qesm Bab Sharqi, Alexandria Governorate, Egypt"},{"name":"Drug Information Center, Tanta Chest Hospital, Ministry of Health, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiro","family":"Katsura","sequence":"additional","affiliation":[{"name":"Department of Surgery, Okinawa Prefectural Nanbu Medical Center & Children\u2019s Medical Center, Haebaru-cho, Shimajiri-gun, Okinawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Kyoto University Graduate School of Medicine\/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Y.","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Min","family":"Cho","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Jiho","family":"Hong","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Sivji","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Toma","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Huangpu District, Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Tsoi","sequence":"additional","affiliation":[{"name":"Accident and Emergency Department, Queen Mary Hospital, High West, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Waligora","sequence":"additional","affiliation":[{"name":"Research Ethics in Medicine Study Group (REMEDY), Department of Philosophy and Bioethics, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manya","family":"Prasad","sequence":"additional","affiliation":[{"name":"Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neera","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Health Sciences Library, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Biostatistics Unit\/FSORC, St Joseph\u2019s Healthcare Hamilton, Hamilton, Ontario, Canada"},{"name":"Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada"},{"name":"Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brundage","sequence":"additional","affiliation":[{"name":"Kingston Health Sciences Centre, Cancer Centre of Southeastern Ontario, Kingston General Hospital, Kingston, Ontario, Canada"},{"name":"Cancer Research Institute, Queen\u2019s University at Kingston, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada"},{"name":"Programs for Health Economics and Outcome Measures, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"ioi180096r1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1200\/JCO.2010.33.1744","article-title":"American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer.","volume":"29","author":"Peppercorn","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"ioi180096r2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J Clin Oncol"},{"key":"ioi180096r3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials.","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"issue":"14","key":"ioi180096r4","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/jnci\/djm073","article-title":"More clinical cancer treatments judged by progression-free rather than overall survival.","volume":"99","author":"Beckman","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"ioi180096r5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrclinonc.2011.156","article-title":"The value of progression-free survival to patients with advanced-stage cancer.","volume":"9","author":"Fallowfield","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"ioi180096r7","first-page":"S0025-6196(16)00125-7","article-title":"Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration\u2019s Approval of Oncology Drugs.","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"ioi180096r8","doi-asserted-by":"publisher","first-page":"e180416","DOI":"10.1001\/jamanetworkopen.2018.0416","article-title":"A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and differences in effect sizes.","volume":"1","author":"Gyawali","year":"2018","journal-title":"JAMA Netw Open"},{"key":"ioi180096r9","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.3747\/co.v18iS2.941","article-title":"Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.","volume":"18","author":"Hotte","year":"2011","journal-title":"Curr Oncol"},{"issue":"9","key":"ioi180096r10","doi-asserted-by":"publisher","first-page":"e012909","DOI":"10.1136\/bmjopen-2016-012909","article-title":"Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol.","volume":"6","author":"Kovic","year":"2016","journal-title":"BMJ Open"},{"key":"ioi180096r11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews.","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"issue":"9760","key":"ioi180096r12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0140-6736(10)60903-8","article-title":"An international registry of systematic-review protocols.","volume":"377","author":"Booth","year":"2011","journal-title":"Lancet"},{"key":"ioi180096r14","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ioi180096r15","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"ioi180096r17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data.","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"3","key":"ioi180096r19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"5","key":"ioi180096r20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"ioi180096r21","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/annonc\/mdq721","article-title":"Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations.","volume":"22","author":"Luckett","year":"2011","journal-title":"Ann Oncol"},{"issue":"14","key":"ioi180096r22","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1200\/JCO.2002.11.005","article-title":"Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.","volume":"20","author":"Biganzoli","year":"2002","journal-title":"J Clin Oncol"},{"issue":"13","key":"ioi180096r23","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1200\/JCO.2004.02.037","article-title":"Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.","volume":"22","author":"Bottomley","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"ioi180096r24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1470-2045(05)70100-5","article-title":"Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial.","volume":"6","author":"Bottomley","year":"2005","journal-title":"Lancet Oncol"},{"issue":"3","key":"ioi180096r25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.","volume":"112","author":"Cameron","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"ioi180096r26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10549-009-0310-8","article-title":"Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.","volume":"117","author":"Zhou","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"34","key":"ioi180096r27","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.","volume":"26","author":"Di Leo","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"ioi180096r28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1185\/03007991003590860","article-title":"Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.","volume":"26","author":"Sherrill","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"ioi180096r29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2407-11-75","article-title":"Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.","volume":"11","author":"Nuzzo","year":"2011","journal-title":"BMC Cancer"},{"issue":"2","key":"ioi180096r30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00432-008-0454-7","article-title":"Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus IV bolus fluorouracil\/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.","volume":"135","author":"Comella","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"ioi180096r31","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/sj.bjc.6601283","article-title":"First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.","volume":"89","author":"Wachters","year":"2003","journal-title":"Br J Cancer"},{"issue":"1","key":"ioi180096r32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/annonc\/mdi009","article-title":"Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.","volume":"16","author":"Lilenbaum","year":"2005","journal-title":"Ann Oncol"},{"issue":"26","key":"ioi180096r33","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1200\/JCO.2007.15.0185","article-title":"Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.","volume":"26","author":"Maruyama","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"ioi180096r34","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/annonc\/mdp031","article-title":"Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.","volume":"20","author":"Sekine","year":"2009","journal-title":"Ann Oncol"},{"issue":"11","key":"ioi180096r35","first-page":"854","article-title":"A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)","volume":"33","author":"Han","year":"2011","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"24","key":"ioi180096r36","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1002\/cncr.27630","article-title":"Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.","volume":"118","author":"Sun","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"ioi180096r37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6","key":"ioi180096r38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1081\/CNV-120025084","article-title":"Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.","volume":"21","author":"Kiebert","year":"2003","journal-title":"Cancer Invest"},{"issue":"6","key":"ioi180096r39","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.","volume":"22","author":"Avril","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"ioi180096r40","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/annonc\/mdu154","article-title":"Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.","volume":"25","author":"Grob","year":"2014","journal-title":"Ann Oncol"},{"issue":"19","key":"ioi180096r41","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi180096r42","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2012.074534","article-title":"Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.","volume":"98","author":"Dimopoulos","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"ioi180096r43","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"ioi180096r44","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer.","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"ioi180096r45","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"ioi180096r46","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer\u2014results from the CALYPSO trial.","volume":"23","author":"Brundage","year":"2012","journal-title":"Ann Oncol"},{"issue":"19","key":"ioi180096r47","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"ioi180096r48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ygyno.2012.06.034","article-title":"Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.","volume":"127","author":"Krasner","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"ioi180096r49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ygyno.2011.08.015","article-title":"Health-related quality of life outcomes of docetaxel\/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.","volume":"123","author":"Pokrzywinski","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"26","key":"ioi180096r50","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer.","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi180096r51","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"22","key":"ioi180096r52","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.","volume":"28","author":"Philip","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"ioi180096r53","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2009.25.8285","article-title":"Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.","volume":"28","author":"Moinpour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"ioi180096r54","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1200\/JCO.2002.10.022","article-title":"Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.","volume":"20","author":"Small","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"ioi180096r55","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159\/Cancer and Leukemia Group B 9480.","volume":"101","author":"Ahles","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"ioi180096r56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00432-010-0864-1","article-title":"Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).","volume":"137","author":"Dawson","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"ioi180096r57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ejca.2011.05.017","article-title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.","volume":"48","author":"Cella","year":"2012","journal-title":"Eur J Cancer"},{"issue":"4","key":"ioi180096r58","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ejca.2012.09.025","article-title":"The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).","volume":"49","author":"Al-Batran","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"ioi180096r59","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S0399-8320(05)82175-X","article-title":"Longitudinal quality of life study in patients with metastatic gastric cancer: analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.","volume":"29","author":"Bonnetain","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"issue":"8","key":"ioi180096r60","first-page":"790","article-title":"Clinical observation on recombinant human vascular endostatin combined with XELOX regimen in the treatment of advanced stomach carcinoma.","volume":"29","author":"Jiang","year":"2009","journal-title":"Tumor"},{"issue":"3","key":"ioi180096r61","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ygyno.2005.09.023","article-title":"Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study.","volume":"100","author":"Long","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"28","key":"ioi180096r62","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"ioi180096r63","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ygyno.2010.08.020","article-title":"Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.","volume":"119","author":"Cella","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1","key":"ioi180096r64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10549-008-0047-9","article-title":"A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.","volume":"115","author":"Fountzilas","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"ioi180096r65","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","article-title":"Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"ioi180096r66","first-page":"166","article-title":"Clinical study of raltitrexed combined with cisplatin for the double-channel chemotherapy in the treatment of patients with advanced colorectal cancer","volume":"26","author":"Chen","year":"2014","journal-title":"Cancer Res Clin"},{"key":"ioi180096r67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2016.01.007","article-title":"Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced\/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.","volume":"93","author":"P\u00e9rol","year":"2016","journal-title":"Lung Cancer"},{"issue":"1","key":"ioi180096r68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer.","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"ioi180096r69","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"ioi180096r70","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer.","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi180096r71","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"21","key":"ioi180096r72","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.","volume":"23","author":"Long","year":"2005","journal-title":"J Clin Oncol"},{"issue":"21","key":"ioi180096r73","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1200\/JCO.2005.10.522","article-title":"Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.","volume":"23","author":"Monk","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"ioi180096r74","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"7965","key":"ioi180096r77","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(76)92112-7","article-title":"Evaluation of quality of life in patients receiving treatment for advanced breast cancer.","volume":"1","author":"Priestman","year":"1976","journal-title":"Lancet"},{"issue":"1","key":"ioi180096r79","doi-asserted-by":"crossref","first-page":"A11","DOI":"10.7326\/ACPJC-2004-140-1-A11","article-title":"Patients at the center: in our practice, and in our use of language.","volume":"140","author":"Guyatt","year":"2004","journal-title":"ACP J Club"},{"issue":"3","key":"ioi180096r80","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/02841860260088764","article-title":"Quality-of-life assessment in oncology: achievements and challenges.","volume":"41","author":"Sprangers","year":"2002","journal-title":"Acta Oncol"},{"issue":"1","key":"ioi180096r81","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.suc.2008.09.015","article-title":"Measuring outcomes in oncology treatment: the importance of patient-centered outcomes.","volume":"89","author":"Oliver","year":"2009","journal-title":"Surg Clin North Am"},{"issue":"32","key":"ioi180096r82","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1200\/JCO.2007.11.3845","article-title":"Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.","volume":"25","author":"Gondek","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"ioi180096r83","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1634\/theoncologist.7-2-120","article-title":"The cancer patient and quality of life.","volume":"7","author":"Bottomley","year":"2002","journal-title":"Oncologist"},{"issue":"5-7","key":"ioi180096r84","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Missing quality of life data in cancer clinical trials: serious problems and challenges.","volume":"17","author":"Bernhard","year":"1998","journal-title":"Stat Med"},{"key":"ioi180096r85","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1111\/j.1524-4733.2007.00278.x","article-title":"Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience.","volume":"10","author":"Osoba","year":"2007","journal-title":"Value Health"},{"key":"ioi180096r6","volume-title":"Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life?","author":"Gutman","year":"2013"},{"key":"ioi180096r13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Green S, eds: The Cochrane Collaboration; 2011: https:\/\/training.cochrane.org\/handbook. Accessed November 25, 2015."},{"key":"ioi180096r16","unstructured":"Abridged Index Medicus. (AIM or \u201cCore Clinical\u201d) Journal Titles. US National Library of Medicine. https:\/\/www.nlm.nih.gov\/bsd\/aim.html. Accessed November 25, 2015."},{"key":"ioi180096r18","unstructured":"LowryR. VassarStats\u2014Kappa as a Measure of Concordance in Categorical Sorting; Kappa with Linear Weighting. 2016. http:\/\/vassarstats.net\/kappa.html. Accessed August 31, 2016."},{"key":"ioi180096r75","unstructured":"Quality of Life Research Associates, LLC.Lung Cancer Symptom Scale (LCSS). http:\/\/www.lcss-ql.com\/. Accessed August 16, 2018."},{"key":"ioi180096r76","unstructured":"EuroQoL Group. EQ-5D Insturments: About EQ-5D. https:\/\/euroqol.org\/eq-5d-instruments\/. Accessed August 16, 2018."},{"key":"ioi180096r78","unstructured":"National Palliative Care Research Center. Karnofsky Performance Scale. http:\/\/www.npcrc.org\/files\/news\/karnofsky_performance_scale.pdf. Accessed August 16, 2018."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2705082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T06:12:54Z","timestamp":1662185574000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2018.4710"}},"subtitle":["A Systematic Review and Quantitative Analysis"],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":85,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2018.4710","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}